Compare Amphastar Pharmaceuticals Inc (AMPH) vs Bank of New York Mellon Corp (BNY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Bank of New York Mellon Corp — how do they compare? Amphastar Pharmaceuticals Inc trades at $18.72 (market cap $826.08M), while Bank of New York Mellon Corp trades at $151.92 (market cap $104.27B). The key difference: Bank of New York Mellon Corp is far larger — about 126.2× Amphastar Pharmaceuticals Inc's market cap, and Bank of New York Mellon Corp pays a 1.4% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | BNY | |
|---|---|---|
Market Cap | $826.08M | $104.27B |
Sector | Health | Financials |
52-Week High | $30.81 | $152.91 |
52-Week Low | $16.87 | $93.72 |
Enterprise Value | $1.22B | — |
Dividend Yield | — | 1.4% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
BNY trades at $151.92, down 0.22% today, with a bullish technical signal and strong earnings momentum after beating estimates for three consecutive quarters. The stock shows robust fundamentals with a 29.21% net income margin and 14.81% ROE, supported by a 19% dividend increase announcement in June 2026. Analyst consensus is mixed with 38.1% buy ratings and a $156 price target, slightly above current levels.
Outlook remains positive given consistent earnings beats and digital asset expansion, but risks include high RSI levels suggesting overbought conditions and sensitivity to interest rate changes. The stock offers steady income growth with dividend hikes, yet investors should monitor execution on large investing outflows and competitive pressures in custody banking.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Bank of New York Mellon Corp
BNY Mellon is a global investment company involved in managing and servicing financial assets throughout the investment lifecycle. The bank provides financial services for institutions, corporations, and individual investors and delivers investment management and investment services in 35 countries and more than 100 markets. BNY Mellon is the largest global custody bank in the world, with about $41.1 trillion in under custody and administration (as of Dec. 31, 2020), and can act as a single point of contact for clients looking to create, trade, hold, manage, service, distribute, or restructure investments. BNY Mellon's asset-management division manages about $2.2 trillion in assets.
Read more on BNY →
